Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BELANTAMAB MAFODOTIN Cause Intentional product use issue? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Intentional product use issue have been filed in association with BELANTAMAB MAFODOTIN (Blenrep). This represents 0.3% of all adverse event reports for BELANTAMAB MAFODOTIN.

7
Reports of Intentional product use issue with BELANTAMAB MAFODOTIN
0.3%
of all BELANTAMAB MAFODOTIN reports
1
Deaths
0
Hospitalizations

How Dangerous Is Intentional product use issue From BELANTAMAB MAFODOTIN?

Of the 7 reports, 1 (14.3%) resulted in death.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BELANTAMAB MAFODOTIN. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does BELANTAMAB MAFODOTIN Cause?

Keratopathy (788) Visual acuity reduced (708) Death (499) Plasma cell myeloma (380) Dry eye (359) Night blindness (317) Photophobia (183) Foreign body sensation in eyes (151) Vision blurred (134) Ocular toxicity (94)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which BELANTAMAB MAFODOTIN Alternatives Have Lower Intentional product use issue Risk?

BELANTAMAB MAFODOTIN vs BELANTAMAB MAFODOTIN-BLMF BELANTAMAB MAFODOTIN vs BELATACEPT BELANTAMAB MAFODOTIN vs BELIMUMAB BELANTAMAB MAFODOTIN vs BELINOSTAT BELANTAMAB MAFODOTIN vs BELUMOSUDIL

Related Pages

BELANTAMAB MAFODOTIN Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue BELANTAMAB MAFODOTIN Demographics